Drawnel FM, Boccardo S, Prummer M, Delobel F, Graff A, Weber M, Gérard R, Badi L, Kam-Thong T, Bu L, Jiang X, Hoflack JC, Kiialainen A, Jeworutzki E, Aoyama N, Carlson C, Burcin M, Gromo G, Boehringer M, Stahlberg H, Hall BJ, Magnone MC, Kolaja K, Chien KR, Bailly J, and Iacone R
Cell Rep 9(3):810-820
Publication Date: October 30, 2014
Product Type: iCell Cardiomyocytes,
Researchers created in vitro models for environmental and genetically-driven diabetic cardiomyopathy. iCell Cardiomyocytes were induced to the cardiomyopathic state through incubation with a diabetic medium while diabetic donor-specific, iPSC-derived MyCell Cardiomyocytes showed the cardiomyopathy phenotype under baseline conditions. A small molecule screen identified molecules that reverted the cardiomyopathy in accordance with the clinical progression of the disease.
This research validates using human iPSC-derived technology in phenotypic drug discovery. It demonstrates the recapitulation of cardiomyopathy through environmental and genetic mechanisms and establishes the utility of phenotypic screens to find molecules and pathways that may provide a therapeutic option.